The Zhitong Finance App learned that Jinfang Pharmaceutical-B (02595) rose more than 8% in early trading. As of press release, it rose 4.42% to HK$28.38, with a turnover of HK$50,3292 million.

According to the news, on October 15, Jingfang Pharmaceutical announced positive progress in several clinical studies of GFH375/VS-7375 (oral KRAS G12D inhibitor) and released the latest data on related studies. Currently, GFH375 has been included as a breakthrough treatment in China by the Drug Evaluation Center of the State Drug Administration of China three times. The indications are KRAS G12D mutant pancreatic cancer, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC), and has entered two registered phase 3 studies for single-drug treatment of pancreatic cancer and NSCLC.

Verastem Oncology, an international partner of Jingfang Pharmaceutical, is expected to launch a registered phase 3 study of multiple VS-7375 combination programs (combined with anti-EGFR therapy or chemotherapy) for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) by the end of this year, with progression-free survival (PFS) and objective remission rate (ORR) as the two main endpoints, and overall survival (OS) as the secondary end point. A consensus has now been reached with the US FDA on the research plan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.